Imperial College London
Alternate

Professor Graham P Taylor

Faculty of Medicine, Department of Infectious Disease

Professor of Human Retrovirology
 
 
 
//

Contact

 

+44 (0)20 7594 3910g.p.taylor Website

 
 
//

Location

 

443Medical SchoolSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Alagaratnam:2020:10.1186/s12981-020-00297-w,
author = {Alagaratnam, J},
doi = {10.1186/s12981-020-00297-w},
journal = {AIDS Research and Therapy},
pages = {1--9},
title = {An observational study of initial HIV RNA decay following initiation of combination antiretroviral treatment during pregnancy},
url = {http://dx.doi.org/10.1186/s12981-020-00297-w},
volume = {17},
year = {2020}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundIn pregnancy, reduction of HIV plasma viral load (pVL) for the prevention of vertical transmission is time-constrained. The study primary objective is to investigate factors associated with faster initial HIV RNA half-life decay when combination antiretroviral treatment (cART) is initiated in pregnancy.MethodsThis was a multicentre, retrospective, observational study, conducted in south England, United Kingdom, between August 2001 and February 2018. Data were extracted from case notes of eligible women initiating cART during the index pregnancy. Anonymised data were collated and analysed centrally. Regression analyses were conducted to determine factors associated with faster HIV RNA half-life decay in the first 14 days after commencing cART (first-phase), and with achieving an undetectable maternal pVL by 36 weeks’ gestation. We then assessed whether HIV- and obstetric- related parameters differed by antiretroviral third agent class and whether the proportions of women with undetectable pVL at 36 weeks’ gestation and at delivery differed by antiretroviral third agent class.ResultsBaseline pVL was the only independent factor associated with faster first-phase HIV RNA half-life decay on commencing cART. Lower pVL on day 14 after starting cART was associated with an increased likelihood of achieving an undetectable pVL by 36 weeks’ gestation. Integrase inhibitor-based cART was associated with a faster first-phase HIV RNA half-life decay on commencing cART. Overall, 73% and 85% of women had an undetectable pVL at 36 weeks’ gestation and at delivery respectively, with no significant difference by antiretroviral third agent class.ConclusionsOnly high baseline pVL independently contributed to a faster rate of first-phase viral half-life decay. pVL at 14 days after initiating cART allows early identification of treatment failure. In the first 14 days after initiating cART in pregnancy, integrase inhibitor-based cART reduced maternal pVL fa
AU  - Alagaratnam,J
DO  - 10.1186/s12981-020-00297-w
EP  - 9
PY  - 2020///
SN  - 1742-6405
SP  - 1
TI  - An observational study of initial HIV RNA decay following initiation of combination antiretroviral treatment during pregnancy
T2  - AIDS Research and Therapy
UR  - http://dx.doi.org/10.1186/s12981-020-00297-w
UR  - https://aidsrestherapy.biomedcentral.com/articles/10.1186/s12981-020-00297-w
UR  - http://hdl.handle.net/10044/1/81303
VL  - 17
ER  -
Download